Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

NCT03009396 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

Sponsor

RedHill Biopharma Limited